<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33438106</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-7322</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>26</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Heart failure reviews</Title>
          <ISOAbbreviation>Heart Fail Rev</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Peripartum cardiomyopathy.</ArticleTitle>
        <Pagination>
          <StartPage>781</StartPage>
          <EndPage>797</EndPage>
          <MedlinePgn>781-797</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10741-020-10060-y</ELocationID>
        <Abstract>
          <AbstractText>Peripartum cardiomyopathy is now increasingly recognized as a cause of heart failure in the later months of pregnancy and early postpartum period. Clinical diagnosis may be challenging as it closely resembles several common medical and obstetric complications. Complex pathogenesis, unpredictable onset, staggered recovery, and unanticipated fetomaternal risks pose unique challenge to clinicians. Prevalence seems to vary with race, geographic location, and diagnostic criteria. The presence of multiple risk factors substantially elevates the risk of PPCM. Transthoracic echocardiographic examination can exclude the majority of the mimickers. Symptomatic presentation is initially limited to, varying grades of low cardiac output syndrome. Rarely, PPCM begins with decompensated heart failure and cardiovascular collapse. Guideline-directed medical therapy involves graded initiation and titration of heart failure medications while ensuring the fetal and neonatal safety. Anesthetic and obstetric management should be individualized to improve fetomaternal outcomes. However, emergent cesarean delivery may be required in women with decompensated heart failure and cardiovascular collapse. An early institution of mechanical circulatory support has shown to improve outcome. Bromocriptine and other experimental drugs designed to target pathogenic pathway have yielded mixed results. A further change in approach to management requires a comprehensive understanding of pathophysiology and fetomaternal safety profiles of heart failure medications.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jha</LastName>
            <ForeName>Nivedita</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynaecology, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jha</LastName>
            <ForeName>Ajay Kumar</ForeName>
            <Initials>AK</Initials>
            <Identifier Source="ORCID">0000-0002-8968-9216</Identifier>
            <AffiliationInfo>
              <Affiliation>Cardiothoracic Division, Department of Anaesthesiology and Critical Care, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry, India. drajaykjha@rediffmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>01</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Heart Fail Rev</MedlineTA>
        <NlmUniqueID>9612481</NlmUniqueID>
        <ISSNLinking>1382-4147</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D009202" MajorTopicYN="Y">Cardiomyopathies</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058725" MajorTopicYN="N">Peripartum Period</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011249" MajorTopicYN="Y">Pregnancy Complications, Cardiovascular</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011644" MajorTopicYN="Y">Puerperal Disorders</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Diagnosis</Keyword>
        <Keyword MajorTopicYN="Y">Differential diagnosis</Keyword>
        <Keyword MajorTopicYN="Y">Epidemiology</Keyword>
        <Keyword MajorTopicYN="Y">Management</Keyword>
        <Keyword MajorTopicYN="Y">Peripartum cardiomyopathy</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33438106</ArticleId>
        <ArticleId IdType="doi">10.1007/s10741-020-10060-y</ArticleId>
        <ArticleId IdType="pii">10.1007/s10741-020-10060-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Demakis JG, Rahimtoola SH (1971) Peripartum cardiomyopathy. Circulation 44:964–968</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4255967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demakis JG, Rahimtoola SH, Sutton GC et al (1971) Natural course of peripartum cardiomyopathy. Circulation 44:1053–1061</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4256828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bauersachs J, Arrigo M, Hilfiker-Kleiner D et al (2016) Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 18:1096–1105</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27338866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pearson GD, Veille GC, Rahimtoola S et al (2000) Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 283:1183–1188</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10703781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hibbard JU, Lindheimer M, Lang RM (1999) A modified definition for peripartum cardiomyopathy and prognosis based on echocardiography. Obstet Gynecol 94:311–316</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10432149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elkayam U, Akhter MW, Singh H, Khan S, Bitar F, Hameed A, Shotan A (2005) Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation 111:2050–2055</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15851613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamiya CA, Kitakaze M, Ishibashi-Ueda H et al (2011a) Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders—results from the Japanese Nationwide Survey of Peripartum Cardiomyopathy. Circ J 75:1975–1981</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21617320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Isezuo SA, Abubakar SA (2007) Epidemiologic profile of peripartum cardiomyopathy in a tertiary care hospital. Ethn Dis 17:228–233</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17682350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brar SS, Khan SS, Sandhu GK et al (2007) Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol 100:302–304</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17631087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pandit V, Shetty S, Kumar A, Sagir A (2009) Incidence and outcome of peripartum cardiomyopathy from a tertiary hospital in South India. Trop Doct 39:168–169</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19535757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fett JD, Christie LG, Carraway RD, Murphy JG (2005) Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc 80:1602–1606</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16342653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gentry MB, Dias JK, Luis A, Patel R, Thornton J, Reed GL (2010) African-American women have a higher risk for developing peripartum cardiomyopathy. J Am Coll Cardiol 55:654–659</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20170791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kolte D, Khera S, Aronow WS et al (2014) Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. J Am Heart Assoc 3:e001056</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24901108</ArticleId>
            <ArticleId IdType="pmc">4309108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Irizarry OC, Levine LD, Lewey J et al (2017) Comparison of clinical characteristics and outcomes of peripartum cardiomyopathy between African American and non-African American women. JAMA Cardiol 2:1256–1260</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29049825</ArticleId>
            <ArticleId IdType="pmc">5815055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kao DP, Hsich E, Lindenfeld J (2013) Characteristics, adverse events, and racial differences among delivering mothers with peripartum cardiomyopathy. JACC Heart Fail 1:409–416</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24163791</ArticleId>
            <ArticleId IdType="pmc">3806506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fett JD, Christie LG, Murphy JG (2006) Brief communication: outcomes of subsequent pregnancy after peripartum cardiomyopathy: a case series from Haiti. Ann Intern Med 145:30–34</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16818926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elkayam U (2014) Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy. J Am Coll Cardiol 64:1629–1636</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25301468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elkayam U, Tummala PP, Rao K et al (2001) Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med 344(21):1567–1571</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11372007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mendelson MA, Chandler J (1992) Postpartum cardiomyopathy associated with maternal cocaine abuse. Am J Cardiol 70:1092–1094</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1414911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gunderson EP, Croen LA, Chiang V, Yoshida CK, Walton D, Go AS (2011) Epidemiology of peripartum cardiomyopathy: incidence, predictors, and outcomes. Obstet Gynecol 118:583–591</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21860287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bianchi WE (2000) Fetomaternal cell trafficking: a new cause of disease? Am J Med Genet 91:22–28</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10751084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bello N, Rendon ISH, Arany Z (2013) The relationship between preeclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis. J Am Coll Cardiol 62:1715–1723</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24013055</ArticleId>
            <ArticleId IdType="pmc">3931606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Safirstein JG, Ro AS, Grandhi S, Wang L, Fett JD, Staniloae C (2012) Predictors of left ventricular recovery in a cohort of peripartum cardiomyopathy patients recruited via the internet. Int J Cardiol 154:27–31</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20863583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hogle KL, Hutton EK, McBrien KA, Barrett JF, Hannah ME (2003) Cesarean delivery for twins: a systematic review and meta-analysis. Am J Obstet Gynecol 188:220–227</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12548221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Afana M, Brinjikji W, Kao D et al (2016) Characteristics and in-hospital outcomes of peripartum cardiomyopathy diagnosed during delivery in the United States from the Nationwide Inpatient Sample (NIS) Database. J Card Fail 22:512–519</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26923643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barasa A, Rosengren A, Sandström TZ, Ladfors L, Schaufelberger M (2017) Heart failure in late pregnancy and postpartum: incidence and long-term mortality in Sweden from 1997 to 2010. J Card Fail 23:370–378</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28069474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lampert MB, Hibbard J, Weinert L, Briller J, Lindheimer M, Lang RM (1993) Peripartum heart failure associated with prolonged tocolytic therapy. Am J Obstet Gynecol 168:493–495</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8438916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ansari AA, Fett JD, Carraway RE, Mayne AE, Onlamoon N, Sundstrom JB (2002) Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. Clin Rev Allergy Immunol 23:301–324</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12402414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bültmann BD, Klingel K, Näbauer M, Wallwiener D, Kandolf R (2005) High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Am J Obstet Gynecol 193:363–365</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16098856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanderson JE, Olsen EG, Gatei D (1986) Peripartum heart disease: an endomyocardial biopsy study. Br Heart J 56:285–291</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3756045</ArticleId>
            <ArticleId IdType="pmc">1236855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fett JD (2006) Viral particles in endomyocardial biopsy tissue from peripartum cardiomyopathy patients. Am J Obstet Gynecol 195:330–1, author reply 331–2</Citation>
        </Reference>
        <Reference>
          <Citation>Rizeq MN, Rickenbacher PR, Fowler MB, Billingham ME (1994) Incidence of myocarditis in peripartum cardiomyopathy. Am J Cardiol 74:474–477</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8059728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forster O, Hilfiker-Kleiner D, Ansari AA et al (2008) Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail 10:861–868</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18768352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Y, Rodriguez JE, Kitsis RN (2013) A microRNA links prolactin to peripartum cardiomyopathy. J Clin Invest 123:1925–1927</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23619357</ArticleId>
            <ArticleId IdType="pmc">3635744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halkein J, Tabruyn SP, Ricke-Hoch M et al (2013) MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest 123:2143–2154</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23619365</ArticleId>
            <ArticleId IdType="pmc">3638905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haghikia A, Podewski E, Libhaber E et al (2013) Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol 108:366</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23812247</ArticleId>
            <ArticleId IdType="pmc">3709080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stapel B, Kohlhaas M, Ricke-Hoch M, Haghikia A, Erschow S, Knuuti J et al (2017) Low STAT3 expression sensitizes to toxic effects of β-adrenergic receptor stimulation in peripartum cardiomyopathy. Eur Heart J 38:349–361</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28201733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haghikia A, Missol-Kolka E, Tsikas D et al (2010) Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart: a key role for ubiquitin-conjugating enzymes. Eur Heart J 32(10):1287–1297</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20965886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maynard SE, Min JY et al (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111:649–658</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12618519</ArticleId>
            <ArticleId IdType="pmc">151901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patten IS, Rana S, Shahul S et al (2012) Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 485:333–338</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22596155</ArticleId>
            <ArticleId IdType="pmc">3356917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Powe CE, Levine RJ, Karumanchi SA (2011) Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 123:2856–2869</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21690502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamiya CA, Kitakaze M, Ishibashi-Ueda H et al (2011b) Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. Results from the Japanese Nationwide survey of peripartum cardiomyopathy. Circ J 75:1975–1981</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21617320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bello NA, Arany Z (2015) Molecular mechanisms of peripartum cardiomyopathy: a vascular/hormonal hypothesis. Trends Cardiovasc Med 25:499–504</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25697684</ArticleId>
            <ArticleId IdType="pmc">4797326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Negoro S, Kunisada K, Fujio Y et al (2001) Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase. Circulation 104:979–981</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11524388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arany Z, Foo SY, Ma Y et al (2008) HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 451:1008–1012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18288196</ArticleId>
            <ArticleId IdType="pmc">18288196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Damp J, Givertz MM, Semigran M et al (2016) IPAC Investigators. Relaxin-2 and soluble Flt1 levels in peripartum cardiomyopathy: results of the multicenter IPAC study. JACC Heart Fail 4:380–388</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26970832</ArticleId>
            <ArticleId IdType="pmc">4851559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson SS, Ayaz S, Levy PD (2015) Relaxin: a novel agent for the treatment of acute heart failure. Pharmacotherapy 35:315–327</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25759289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGuane JT, Danielson LA, Debrah JE, Rubin JP, Novak J, Conrad KP (2011) Angiogenic growth factors are new and essential players in the sustained relaxin vasodilatory pathway in rodents and humans. Hypertension 57:1151–1160</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21536992</ArticleId>
            <ArticleId IdType="pmc">3114044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sliwa K, Förster O, Libhaber E et al (2006) Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J 27:441–446</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16143707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reddy A, Suri S, Sargent IL, Redman CW, Muttukrishna S (2009) Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and pre-eclampsia. PLoS ONE 4:e4453</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19412349</ArticleId>
            <ArticleId IdType="pmc">2675175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim R, Acharya R, Delpachitra P et al (2015) Activin and NADPH-oxidase in preeclampsia: insights from in vitro and murine studies. Am J Obstet Gynecol 212:86.e1–12</Citation>
        </Reference>
        <Reference>
          <Citation>Selle T, Renger I, Labidi S, Bultmann I, Hilfiker-Kleiner D (2009) Reviewing peripartum cardiomyopathy: current state of knowledge. Future Cardiol 5:175–189</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19371191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warraich RS, Sliwa K, Damasceno A, Carraway R, Sundrom B et al (2005) Impact of pregnancy-related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy. Am Heart J 150:263–269</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16086928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fett JD, Sundstrom BJ, Etta King M, Ansari AA (2002) Mother-daughter peripartum cardiomyopathy. Int J Cardiol 86:331–332</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12419575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pierce JA, Price BO, Joyce JW (1963) Familial occurrence of postpartal heart failure. Arch Intern Med 111:6515</Citation>
        </Reference>
        <Reference>
          <Citation>Herman DS, Lam L, Taylor MR et al (2012) Truncations of titin causing dilated cardiomyopathy. N Engl J Med 366:619–628</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22335739</ArticleId>
            <ArticleId IdType="pmc">3660031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ware JS, Li J, Mazaika E et al (2016) IMAC-2 and IPAC Investigators. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med 374:233–241</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26735901</ArticleId>
            <ArticleId IdType="pmc">4797319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gemici G, Tezcan H, Fak AS, Oktay A (2004) Peripartum cardiomyopathy presenting with repetitive monomorphic ventricular tachycardia. Pacing Clin Electrophysiol 27:557–558</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15078417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sliwa K, Mebazaa A, Hilfiker-Kleiner D et al (2017) Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. Eur J Heart Fail 19:1131–1141</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28271625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanous D, Siu SC, Mason J et al (2010) B-type natriuretic peptide in pregnant women with heart disease. J Am Coll Cardiol 56:1247–1253</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20883932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bauersachs J, König T, van der Meer P et al (2019) Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 21(7):827–843</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31243866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biteker M, Özlek B, Özlek E et al (2020) Predictors of early and delayed recovery in peripartum cardiomyopathy: a prospective study of 52 Patients. J Matern Fetal Neonatal Med 33(3):390–397</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29945487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li W, Li H, Long Y (2016) Clinical characteristics and long-term predictors of persistent left ventricular systolic dysfunction in peripartum cardiomyopathy. Can J Cardiol 32:362–368</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26586094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu CL, Li YB, Zou YG, Zhang JM, Chen JB, Liu J et al (2007) Troponin T measurement can predict persistent left ventricular dysfunction in peripartum cardiomyopathy. Heart 93:488–490</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17065185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Talle MA, Buba F, Anjorin CO (2014) Prevalence and aetiology of left ventricular thrombus in patients undergoing transthoracic echocardiography at the University of Maiduguri Teaching Hospital. Adv Med 731936</Citation>
        </Reference>
        <Reference>
          <Citation>Sliwa K, Skudicky D, Bergemann A, Candy G, Puren A, Sareli P (2000) Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. J Am Coll Cardiol 35:701–705</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10716473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karaye KM, Sani MU (2008) Factors associated with poor prognosis among patients admitted with heart failure in a Nigerian tertiary medical centre: a cross-sectional study. BMC Cardiovasc Disord 8:16</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18644161</ArticleId>
            <ArticleId IdType="pmc">2492836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lima FV, Parikh PB, Zhu J, Yang J, Stergiopoulos K (2015) Association of cardiomyopathy with adverse cardiac events in pregnant women at the time of delivery. JACC Heart Fail 3(3):257–266</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25742764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McNamara DM, Elkayam U, Alharethi R et al (2015) IPAC investigators. Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol 66:905–914</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26293760</ArticleId>
            <ArticleId IdType="pmc">5645077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duncker D, Haghikia A, König T et al (2014) Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator. Eur J Heart Fail 16:1331–1336</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25371320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saltzberg MT, Szymkiewicz S, Bianco NR (2012a) Characteristics and outcomes of peripartum versus nonperipartum cardiomyopathy in women using a wearable cardiac defibrillator. J Card Fail 18:21–27</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22196837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whitehead SJ, Berg CJ, Chang J (2003) Pregnancy-related mortality due to cardiomyopathy: United States, 1991–1997. Obstet Gynecol 102:1326–1331</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14662222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goland S, Modi K, Bitar F et al (2009) Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail 15:645–650</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19786252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mallikethi-Reddy S, Akintoye E, Trehan N et al (2017) Burden of arrhythmias in peripartum cardiomyopathy: analysis of 9841 hospitalizations. Int J Cardiol 235:114–117</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28268089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Regitz-Zagrosek V, Roos-Hesselink JW, et al (2018) ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 39(34):3165–3241</Citation>
        </Reference>
        <Reference>
          <Citation>Duan L, Ng A, Chen W et al (2017) β-blocker exposure in pregnancy and risk of fetal cardiac anomalies. JAMA Intern Med 177(6):885–887</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28418448</ArticleId>
            <ArticleId IdType="pmc">5818837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ersbøll AS, Hedegaard M, Søndergaard L, Ersbøll M, Johansen M (2014) Treatment with oral beta-blockers during pregnancy complicated by maternal heart disease increases the risk of fetal growth restriction. BJOG 121(5):618–626</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24400736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bateman BT, Patorno E, Desai RJ et al (2016) Late pregnancy β blocker exposure and risks of neonatal hypoglycemia and bradycardia. Pediatrics 138(3):e20160731</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27577580</ArticleId>
            <ArticleId IdType="pmc">5005024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ponikowski P, Voors AA, Anker SD et al (2016) Authors/Task Force Members, Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18:891–975</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27207191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haghikia A, Tongers J, Berliner D et al (2016) Early ivabradine treatment in patients with acute peripartum cardiomyopathy: subanalysis of the German PPCM registry. Int J Cardiol 216:165–167</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27156059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Libhaber E, Sliwa K, Bachelier K, Lamont K, Bohm M (2015) Low systolic blood pressure and high resting heart rate as predictors of outcome in patients with peripartum cardiomyopathy. Int J Cardiol 190:376–382</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25966297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sieweke JT, Pfeffer TJ, Berliner D, et al (2018) Cardiogenic shock complicating peripartum cardiomyopathy: importance of early left ventricular unloading and bromocriptine therapy. Eur Heart J Acute Cardiovasc Care 2048872618777876</Citation>
        </Reference>
        <Reference>
          <Citation>Labbene I, Arrigo M, Tavares M et al (2017) Decongestive effects of levosimendan in cardiogenic shock induced by postpartum cardiomyopathy. Anaesth Crit Care Pain Med 36:39–42</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27436451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biteker M, Duran NE, Kaya H et al (2011) Effect of levosimendan and predictors of recovery in patients with peripartum cardiomyopathy, a randomized clinical trial. Clin Res Cardiol 100:571–577</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21197536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hellgren M (2003) Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost 29:125–130</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12709915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Napporn AG, Kane A, Damorou JM et al (2000) Intraventricular thrombosis complicating peri-partum idiopathic myocardiopathy. Ann Cardiol Angeiol (Paris) 49:309–314</Citation>
        </Reference>
        <Reference>
          <Citation>Jha P, Jha S, Millane TA (2005) Peripartum cardiomyopathy complicated by pulmonary embolism and pulmonary hypertension. Eur J Obstet Gynecol Reprod Biol 123:121–123</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15893870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bozkurt B, Colvin M, Cook J et al (2016) Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation 134:e579-646</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27832612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ntusi NB, Badri M, Gumedze F, Sliwa K (2015) Mayosi BM (2015) Pregnancy-associated heart failure: a comparison of clinical presentation and outcome between hypertensive heart failure of pregnancy and idiopathic peripartum cardiomyopathy. PLoS ONE 10:e0133466</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26252951</ArticleId>
            <ArticleId IdType="pmc">4529210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hilfiker-Kleiner D, Haghikia A, Berliner D et al (2017) Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J 38:2671–2679</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28934837</ArticleId>
            <ArticleId IdType="pmc">5837241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sliwa K, Blauwet L, Tibazarwa K et al (2010) Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 121:1465–1473</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20308616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haghikia A, Schwab J, Vogel-Claussen J (2019) Bromocriptine Treatment in Patients with Peripartum Cardiomyopathy and Right Ventricular Dysfunction. Clin Res Cardiol 108(3):290–297</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30121697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tremblay-Gravel M, Marquis-Gravel G, Avram R (2019) The effect of bromocriptine on left ventricular functional recovery in peripartum cardiomyopathy: insights from the BRO-HF retrospective cohort study. ESC Heart Fail 6(1):27–36</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30565890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moulig V, Pfeffer TJ, Ricke-Hoch M et al (2019) Long-term follow-up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular co-morbidities. Eur J Heart Fail 21(12):1534–1542</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31724271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hilfiker-Kleiner D, Haghikia A, Masuko D et al (2017) Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy. Eur J Heart Fail 19(12):1723–1728</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28345302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sieweke JT, Pfeffer TJ, Berliner D et al (2020) Cardiogenic shock complicating peripartum cardiomyopathy: importance of early left ventricular unloading and bromocriptine therapy. Eur Heart J Acute Cardiovasc Care 9(2):173–182</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29792513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sliwa K, Skudicky D, Candy G, Bergemann A, Hopley M, Sareli P (2002) The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail 4:305–309</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12034156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skudicky D, Bergemann A, Sliwa K, Candy G, Sareli P (2001) Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. Circulation 103:1083–1088</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11222470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Champion S, Lapidus N, Cherié G, Spagnoli V, Oliary J, Solal AC (2014) Pentoxifylline in heart failure: a meta-analysis of clinical trials. Cardiovasc Ther 32:159–162</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24758396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beadle RM, Williams LK, Kuehl M et al (2015) Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy. JACC Heart Fail 3:202–211</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25650370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Metra M, Teerlink JR, Cotter G et al (2019) Effects of serelaxin in patients with acute heart failure. N Engl J Med 381(8):716–726</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31433919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teerlink JR, Cotter G, Davison BA et al (2013) RELAXin in acute heart failure (RELAX-AHF) investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381:29–39</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23141816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Łasińska-Kowaraa M, Lango R, Kowalik M, Jarmoszewicz KŁ (2014) Accelerated heart function recovery after therapeutic plasma exchange in patient treated with biventricular mechanical circulatory support for severe peripartum cardiomyopathy. Eur J Cardiothorac Surg 46:1035–1036</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24780740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thadhani R, Hagmann H, Schaarschmidt W et al (2016) Removal of soluble fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia. J Am Soc Nephrol 27:903–913</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26405111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saltzberg MT, Szymkiewicz S, Bianco NR (2012b) Characteristics and outcomes of peripartum versus non-peripartum cardiomyopathy in women using a wearable cardiac defibrillator. J Card Fail 18:21–27</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22196837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rasmusson K, Brunisholz K, Budge D et al (2012) Peripartum cardiomyopathy: post-transplant outcomes from the United Network for Organ Sharing Database. J Heart Lung Transplant 31:180–186</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22305380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davies MR, Cousins J (2009) Cardiomyopathy and anesthesia. Contin Educ Anaesth Crit Care Pain 9:189–193</Citation>
        </Reference>
        <Reference>
          <Citation>Cunningham FG, MacDonald PC, Gant NF, Leveno KJ, Gilstrap LC, Hankins GDV, Clark SL (1997) Cesarean delivery and cesarean hysterectomy. Williams Obstetrics 20th edition, Cunningham et al, Appleton and Lange, Stamford, Conn, 509-531</Citation>
        </Reference>
        <Reference>
          <Citation>Perkins JT (1992) Hemolytic disease of the newborn. In: Gleicher N (ed) Principles and practice of medical therapy in pregnancy, 2nd edn. Stamford Conn, Appleton &amp; Lange, pp 1040–1045</Citation>
        </Reference>
        <Reference>
          <Citation>Mielniczuk LM, Williams K, Davis DR et al (2006) Frequency of peripartum cardiomyopathy. Am J Cardiol 97:1765–1768</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16765131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pillarisetti J, Kondur A, Alani A et al (2014) Peripartum cardiomyopathy: predictors of recovery and current state of implantable cardioverter-defibrillator use. J Am Coll Cardiol 63:2831–2839</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24814494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sliwa K, Fett J, Elkayam U (2006) Peripartum cardiomyopathy. Lancet 368:687–693</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16920474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J, Dharmarajan K, Wang Y, Krumholz HM (2013) National trends in heart failure hospital stay rates, 2001 to 2009. J Am Coll Cardiol 61:1078–1088</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23473413</ArticleId>
            <ArticleId IdType="pmc">3939721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amos AM, Jaber WA, Russell SD (2006) Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J 152(3):509–513</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16923422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biteker M, Ilhan E, Biteker G, Duman D, Bozkurt B (2012) Delayed recovery in peripartum cardiomyopathy: an indication for long-term follow-up and sustained therapy. Eur J Heart Fail 14(8):895–901</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22588321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sliwa K, Petrie MC, Hilfiker-Kleiner D et al (2018) Long-term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peri- partum Cardiomyopathy. Eur J Heart Fail 20:951–962</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29578284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis M, Kawamoto K, Langen E, Jackson E (2017) Breastfeeding is not associated with worse outcomes in peripartum cardiomyopathy. J Am Coll Cardiol 69(Suppl):842</Citation>
        </Reference>
        <Reference>
          <Citation>Koczo A, Marino A, Jeyabalan A et al (2019) Breastfeeding, cellular immune activation, and myocardial recovery in peripartum cardiomyopathy. J Am Coll Cardiol Basic Trans Science 4:291–300</Citation>
        </Reference>
        <Reference>
          <Citation>Black RE, Victora CG, Walker SP et al (2013) Maternal and child under nutrition and overweight in low-income and middle-income countries. Lancet 382:427–451</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23746772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Victora CG, Bahl R, Barros AJ et al (2016) Breast- feeding in the 21st century: epidemiology, mechanisms, and lifelong effect. Lancet 387:475–490</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26869575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barbosa MM, Freire CM, Nascimento BR et al (2012) Rest left ventricular function and contractile reserve by dobutamine stress echocardiography in peripartum cardiomyopathy. Rev Port Cardiol 31:287–293</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22417720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ostrzega E, Elkayam U (1995) Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy: results of a survey. Circulation, 92 SI: 333</Citation>
        </Reference>
        <Reference>
          <Citation>Lampert M, Weinert L, Hibbard J, Korcarz C, Lindheimer M, Lang RM (1997) Contractile reserve in patients with peripartum cardiomyopathy and recovered left ventricular function. Am J Obstet Gynecol 176:189–195</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9024112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yaméogo NV, Samadoulougou AK, Kagambèga LJ (2018) Maternal and fetal prognosis of subsequent pregnancy in Black African women with peripartum cardiomyopathy. BMC Cardiovasc Disord 18(1):119</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29914408</ArticleId>
            <ArticleId IdType="pmc">6006934</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
